Drug intelligence / Profile preview

AV805

Development stage: Preclinical
Lead developer: Aeovian Pharmaceuticals
Modality: Small Molecules

Overview

AV805 is a central nervous system (CNS)-penetrant, selective small molecule inhibitor of mechanistic target of rapamycin complex 1 (mTORC1). Developed by Aeovian Pharmaceuticals, it is designed to address neurodegenerative diseases and genetic disorders characterized by excessive mTORC1 activation. Unlike many other mTOR inhibitors, AV805 is specifically engineered to cross the blood-brain barrier, distinguishing it from Aeovian's peripheral-targeting compounds. The drug is currently in IND-enabling studies, targeting biological aging and related neurological conditions.

Targets

Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on AV805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV805.

Explore the full profile